Journal of Clinical Oncology
Articles in this Issue
Primary analysis of pembrolizumab combined with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer: The NOGGO PERCEPTION phase II study.
5595 Background: Low-grade serous ovarian cancer (LGSOC), a rare ovarian malignancy, exhibits a very limited responsivenes...
A phase 2 trial of cetuximab for patients with locally advanced/metastatic chordoma.
11527 Background: Unresectable/metastatic chordoma is a rare notochordal malignancy with no approved systemic treatments....
Epidemiological trends and burden of retinoblastoma mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e22610 Background: Retinoblastoma is a rare but highly curable pediatric malignancy, yet mortality remains substantial in...
G8 geriatric score as a determinant of survival and treatment in metastatic breast cancer.
e24121 Background: Metastatic breast cancer in elderly women remains a major therapeutic challenge, with frequent undertre...
Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial.
533 Background: While dual anti-HER2 therapy is standard in the adjuvant setting for HER2-positive early breast cancer, tr...
Efficacy and safety of trifluridine–tipiracil with VEGF inhibitors and EGFR inhibitors in metastatic unresectable colorectal cancer: A network meta-analysis.
e15629 Background: Introduction:Metastatic unresectable colorectal cancer (mCRC) poses a particular challengewhen patients...
Effect of perioperative esketamine on postoperative recovery in breast cancer patients undergoing modified radical mastectomy: A systematic review and meta-analysis.
e24074 Background: Modified radical mastectomy (MRM) is associated with significant acute postoperative and potential chro...
Accessibility of mandated coverage: Insurer and care team perspectives on barriers for cancer patients to receive insurance coverage for fertility preservation despite state-mandated coverage.
e23038 Background: Several states require select insurers to cover fertility preservation for enrollees at risk of iatroge...
B-cell Enrollment Efficiency Program (BEEP): Streamlining accrual to early-phase lymphoma trials at a single center.
e19084 Background: Enrolling patients with lymphoma into clinical trials is challenging due to stringent organ function el...
Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.
4619 Background: To evaluate neoadjuvant sacituzumab govitecan (SG), followed by radical cystectomy (RC), in patients with...
Thromboelastography-guided platelet transfusion and associations with utilization and outcomes in patients with hematologic malignancies.
6590 Background: Thromboelastography (TEG) is a viscoelastic assay assessing clot formation and global hemostasis. In pati...
Refining breast cancer risk stratification for selection of women at intermediate to high risk for supplemental MRI screening using artificial intelligence.
10564 Background: Supplemental MRI screening for women at increased breast cancer risk can detect additional cancers that...
Efficacy and safety of combined transarterial embolization/chemoembolization and hepatic arterial infusion chemotherapy versus transarterial embolization/chemoembolization alone in unresectable neuroendocrine tumor liver metastases.
e16309 Background: Neuroendocrine Tumor Liver Metastases (NETLM) represent the most critical prognostic factor in patients...
Survival outcomes of stage IIB/IIC cutaneous melanoma treated with wide local excision and adjuvant immunotherapy without sentinel lymph node biopsy.
9563 Background: The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) reported no significant difference in 10-year...
TIDAL: A phase II study of the DLL3-directed T-cell engager tarlatamab in DLL3-positive metastatic prostate cancer.
TPS5142 Background: T-cell engagers directed at canonical prostate adenocarcinoma surface antigens (e.g., STEAP1, KLK2) ha...
Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L cisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update on Duravelo-1 B7.
4564 Background: Zelenectide pevedotin (zele, formerly BT8009) is a highly selective Bicycle Drug Conjugate (BDC) targetin...
Experience of Spanish centers with echoendoscopically implanted <sup>32</sup> P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma.
4232 Background: Phosphorous 32 microparticle ( 32 P) brachytherapy delivered by e...
Outcomes of first-line immune checkpoint inhibitor combinations versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A meta-analysis.
e16243 Background: This meta-analysis compares survival and safety outcomes of FDA-approved first-line ICI combinations ve...
Impact of the COVID-19 pandemic on outcomes in malignant bowel obstruction: A National Inpatient analysis using explainable machine learning (2020–2023).
e13572 Background: Malignant bowel obstruction (MBO) is a high-mortality complication of advanced abdominal and pelvic mal...
A phase I window-of-opportunity trial of intraperitoneal, intratumoral lipopolysaccharide in peritoneal metastases: Safety and immune remodeling from the RIOT-1 study.
2603 Background: Peritoneal metastases (PM) from gastrointestinal malignancies exhibit immune exclusion and limited respon...
Baseline brain metastases as a prognostic factor in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: A systematic review and meta-analysis.
e20139 Background: Extensive-stage small cell lung cancer (ES-SCLC) frequently presents with brain metastases, affecting a...
Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.
4624 Background: In the Phase 3 POTOMAC study (NCT03528694), 1 year of D in combination with BCG (I + M) resulted in a sta...
Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.
e19521 Background: Ciltacabtagene autoleucel (Carvykti, cilta-cel) is a BCMA-directed CAR-T associated with deep and durab...
Modulation of PD-1 and PD-L1 expression on peripheral blood T-cells by novel rotavirus variants.
2658 Background: Promising oncolytic viruses are typically evaluated based on their direct cytotoxic effects on cancer cel...
Pan-cancer <i>KRAS</i> atlas of 9,056 Chinese patients: Subtype-specific immuno-genomic profiling to guide G12C, G12D, and pan- <i>KRAS</i> strategies.
3128 Background: KRAS therapy is shifting from allele-specific inhibitors to pan-...